EuroBiotech: More Articles of Note

> C4X Discovery raised £10 million ($13 million) to support its efforts to identify drug discovery targets. Statement 

> Gene therapy startup Horama completed its series B, which topped out at €22.5 million ($26.3 million) after V-Bio Ventures joined the syndicate. Release

> Galapagos and MorphoSys moved anti-IL-17C antibody MOR106 into a phase 1 subcutaneous bridging study. Statement

> Galapagos raised €296 million ($346 million) through a public stock offering. The offering follows a sharp rise in Galapagos’ stock price. Release 

> Nanobiotix presented updated data from a phase 1/2 trial of NBTXR3 in patients with locally advanced head and neck cancers. The readout suggests the radiotherapy-activated treatment triggers sustained responses. Statement